Please wait a minute...
文章检索
预防医学  2026, Vol. 38 Issue (6): 583-587    DOI: 10.19485/j.cnki.issn2096-5087.2026.06.010
  论著 本期目录 | 过刊浏览 | 高级检索 |
丽水市新生儿先天性心脏病免费筛查的经济学评价
殷畅1, 叶佳佳2, 杨永梅1
1.温州医科大学医学人文与管理学院,浙江 温州 325025;
2.丽水市妇幼保健院,浙江 丽水 323000
Economic evaluation of free newborn screening for congenital heart disease in Lishui City
YIN Chang1, YE Jiajia2, YANG Yongmei1
1. School of Medical Humanities and Management, Wenzhou Medical University, Wenzhou, Zhejiang 325025, China;
2. Lishui Maternal and Child Health Care Hospital, Lishui, Zhejiang 323000, China
全文: PDF(798 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 评价浙江省丽水市新生儿先天性心脏病(CHD)免费筛查政策的卫生经济学价值,为优化卫生资源配置、完善基本公共卫生服务提供依据。方法 通过丽水市妇幼保健院新生儿CHD筛查登记系统收集2022—2024年丽水市新生儿CHD免费筛查资料,以未筛查为对照,测算成本、效益和效用,按3%贴现率贴现至2022年。采用效益成本比(BCR)和增量成本效用比(ICUR)进行经济评价,并对结果进行单因素敏感性分析和蒙特卡洛概率敏感性分析。结果 2022—2024年丽水市新生儿CHD免费筛查44 343人,初筛阳性4 202人,确诊CHD 367例,假阳性3 835人。贴现后项目筛查总成本为214.10万元,总效益为1 314.82万元,净健康效用增益为245.32质量调整生命年(QALY)。BCR为6.14,ICUR为8 727元/QALY,低于丽水市人均国内生产总值支付意愿阈值(78 978元/QALY)。敏感性分析结果显示,关键参数变动后BCR均大于1,ICUR均低于支付意愿阈值,结果稳健。结论 丽水市新生儿CHD免费筛查政策具有良好的经济性和可推广性,建议通过耗材集采与信息化闭环管理进一步优化成本与效益。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
殷畅
叶佳佳
杨永梅
关键词 新生儿先天性心脏病筛查经济学评价    
AbstractObjective To evaluate the health economic value of the free screening policy for congenital heart disease (CHD) among newborns in Lishui City, Zhejiang Province, so as to provide the evidence for optimizing health resource allocation and improving basic public health services. Methods Data on free CHD screening in Lishui City from 2022 to 2024 were collected through the Newborn CHD Screening Registration System of Lishui Maternity and Child Health Care Hospital. With no screening as the control, costs, benefits and utilities were calculated and discounted to the year 2022 at a discount rate of 3%. Benefit-cost ratio (BCR) and incremental cost-utility ratio (ICUR) were used for economic evaluation. One-way sensitivity analysis and Monte Carlo probabilistic sensitivity analysis were conducte. Results A total of 44 343 newborns were screened for free CHD in Lishui City from 2022 to 2024. Among them, 4 202 tested positive on initial screening, 367 were confirmed as CHD cases, and 3 835 were false-positive. After discounting, the total screening cost was 2.141 0 million yuan, with total benefits of 13.148 2 million yuan and the net health utility gain was 245.32 quality-adjusted life year (QALY). The BCR was 6.14, and the ICUR was 8 727 yuan/QALY, which was lower than the willingness-to-pay threshold of per capita gross domestic product in Lishui City (78 978 yuan/QALY). Sensitivity analysis showed that the BCR remained above 1 and the ICUR remained below the willingness-to-pay threshold across all key parameters, indicating robust results. Conclusions The free newborn CHD screening policy in Lishui City presents favorable economic efficiency and scalability. It is recommended to further optimize costs and benefits through centralized procurement of consumables and closed-loop information management.
Key wordsnewborn    congenital heart disease    screening    economic evaluation
收稿日期: 2026-01-09      修回日期: 2026-03-17     
中图分类号:  R197.1  
基金资助:国家社会科学基金项目(22BGL250)
作者简介: 殷畅,硕士研究生在读,公共事业管理专业
通信作者: 杨永梅,E-mail:yangyongmei@wmu.edu.cn   
引用本文:   
殷畅, 叶佳佳, 杨永梅. 丽水市新生儿先天性心脏病免费筛查的经济学评价[J]. 预防医学, 2026, 38(6): 583-587.
YIN Chang, YE Jiajia, YANG Yongmei. Economic evaluation of free newborn screening for congenital heart disease in Lishui City. Preventive Medicine, 2026, 38(6): 583-587.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2026.06.010      或      https://www.zjyfyxzz.com/CN/Y2026/V38/I6/583
[1] HOFFMAN J I E,KAPLAN S.The incidence of congenital heart disease[J].J Am Coll Cardiol,2002,39(12):1890-1900.
[2] KEMPER A R,MAHLE W T,MARTIN G R,et al.Outcome of pulse oximetry screening for critical congenital heart disease[J].N Engl J Med,2011,364(16):1599-1608.
[3] 胡晓静,马晓静,曾子倩,等.应用脉搏血氧饱和度或/和临床评估(心脏杂音听诊)筛查新生儿危重型先天性心脏病的系统评价和Meta分析[J].中国循证儿科杂志,2020,15(5):325-332.
[4] 陆天玮,胡晓静,张崇凡,等.新生儿危重症先天性心脏病筛查的卫生经济学系统评价[J].中国循证儿科杂志,2022,17(3):195-201.
[5] PETERSON C,DAWSON A,GROSSE S D,et al.Hospitalizations,costs,and mortality among infants with critical congenital heart disease:how important is timely detection[J].Birth Defects Res A Clin Mol Teratol,2013,97(10):664-672.
[6] ABOUK R,GROSSE S D,AILES E C,et al.Association of US state implementation of newborn screening policies for critical congenital heart disease with early infant cardiac deaths[J].JAMA,2017,318(21):2111-2118.
[7] 那艺诺,李艺,王丹,等.基于支付意愿法中国统计生命价值系统评价[J].中国公共卫生,2025,41(2):239-245.
[8] 顾学范,王家军,叶军,等.筛查新生儿苯丙酮尿症和先天性甲状腺机能减低症的成本效益分析[J].中华预防医学杂志,2000,34(3):20-22.
[9] BRIGGS A H,WEINSTEIN M C,FENWICK E A,et al.Model parameter estimation and uncertainty analysis:a report of the ISPOR-SMDM modeling good research practices task force working group-6[J].Med Decis Making,2012,32(5):722-732.
[10] REEDER M R,KIM J,NANCE A,et al.Evaluating cost and resource use associated with pulse oximetry screening for critical congenital heart disease:empiric estimates and sources of variation[J].Birth Defects Res A Clin Mol Teratol,2015,103(11):962-971.
[11] MUKERJI A,SHAFEY A,JAIN A,et al.Pulse oximetry screening for critical congenital heart defects in Ontario,Canada:a cost-effectiveness analysis[J].Rev Can De Sante Publique,2020,111(5):804-811.
[12] PETERSON C,GROSSE S D,OSTER M E,et al.Cost-effectiveness of routine screening for critical congenital heart disease in US newborns[J].Pediatrics,2013,132(3):595-603.
[13] EWER A K,FURMSTON A T,MIDDLETON L J,et al.Pulse oximetry as a screening test for congenital heart defects in newborn infants:a test accuracy study with evaluation of acceptability and cost-effectiveness[J].Health Technol Assess,2012,16(2):1-184.
[14] LONDOÑO TRUJILLO D,SANDOVAL REYES N F,TABORDA RESTREPO A,et al.Cost-effectiveness analysis of newborn pulse oximetry screening to detect critical congenital heart disease in Colombia[J/OL].Cost Eff Resour Alloc,2019,17[2026-03-17].http://doi.org/10.1186/s12962-019-0179-2.
[15] 丽扎·江阿别克,阿扎玛提·阿扎提,马荣,等.先天性心脏病患儿家庭经济负担及影响因素分析[J].中国卫生经济,2024,43(2):62-66.
[1] 杨利, 滕楠, 张若娣, 陈腾伟, 许圆圆. 台州市中小学生结核分枝杆菌潜伏感染筛查结果[J]. 预防医学, 2026, 38(6): 564-567.
[2] 江燕, 王荣, 温佳鑫. 基于决策树-马尔可夫模型的南京市老年糖尿病患者肺结核筛查成本效用分析[J]. 预防医学, 2026, 38(6): 545-549.
[3] 刘慧敏, 钱永刚, 陈文婕, 葛丽岩. 内蒙古自治区农村上消化道癌机会性筛查结果[J]. 预防医学, 2026, 38(6): 639-642.
[4] 肖筱, 陈彬, 刘巧, 沈鑫. 我国结核分枝杆菌潜伏感染筛查与预防性治疗进展[J]. 预防医学, 2026, 38(5): 433-437.
[5] 张业晴, 于全骥, 刘巧. 江苏省结核分枝杆菌潜伏感染防治策略、实践与挑战[J]. 预防医学, 2026, 38(5): 438-441.
[6] 李佳文, 熊小梅, 王育珊. 身体测量指标筛查代谢综合征的效果比较[J]. 预防医学, 2025, 37(2): 163-167,172.
[7] 梁薇, 任梦婷, 张文科, 杨琳, 王红雨. 滁州市中小学生脊柱侧弯筛查结果[J]. 预防医学, 2024, 36(7): 607-610.
[8] 蒋鸣孝, 李剑, 黄旭云. 上城区结直肠癌筛查结果分析[J]. 预防医学, 2024, 36(6): 501-505.
[9] 和金金, 朱陈, 潘婷婷, 黄文雯, 蒋秉洁, 余炜燕, 王乐, 吴维妙, 杭栋, 杜灵彬. 定性和定量粪便免疫化学试验筛查结直肠癌效果评价[J]. 预防医学, 2024, 36(4): 317-321.
[10] 胡军路, 冯慧慧, 陈文迪. 献血前健康筛查软件介绍及应用[J]. 预防医学, 2024, 36(4): 362-364.
[11] 牛贺, 王荣环, 鲍筝. 北京市通州区0~3岁儿童发育筛查结果[J]. 预防医学, 2024, 36(2): 165-168.
[12] 沈方力, 茅俭英, 孟杨, 朱礼明, 柏红, 汤德珍, 刘世友. 宝山区居民结直肠癌筛查结果分析[J]. 预防医学, 2024, 36(10): 869-872,877.
[13] 徐亚华, 吴斌. 兰溪市120例HIV抗体筛查阳性样本确证结果分析[J]. 预防医学, 2023, 35(6): 538-540.
[14] 王川, 赵秋玲, 马艳艳, 高倩, 赵月, 罗佳. 2012—2021年朝阳区新生儿遗传代谢病筛查工作质量评价[J]. 预防医学, 2023, 35(11): 1001-1004.
[15] 文彩荷, 俞黎铭, 柴芸. 重度窒息新生儿55例预后分析[J]. 预防医学, 2023, 35(10): 899-902.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed